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Abstract
Background: Immunoassays for Plasmodium detection are, presently, most frequently based on monoclonal
antibodies (MAbs); Polyclonal antibodies (PAbs), which are cheaper to develop and manufacture, are much less
frequently used. In the present study we describe a sandwich ELISA assay which is capable of detecting P. vivax Lactate
Dehydrogenase (LDH) in clinical blood samples, without cross reacting with those infected with P. falciparum.
Methods: Two recombinant proteins were produced from different regions of the P. vivax LDH gene. Two sandwich
ELISA assay were then designed: One which uses mouse anti-LDH 1-43aa PAbs as primary antibodies (“Test 1”) and
another which uses anti-LDH 35-305aa PAbs (“Test 2”) as the primary antibodies. Rabbit anti-LDH 1-43aa PAbs were
used as capture antibodies in both ELISA assays. Blood samples taken from P. vivax and P. falciparum infected patients
(confirmed by light microscopy) were analysed using both tests.
Results: “Test 2” performed better at detecting microscopy-positive blood samples when compared to “Test 1”,
identifying 131 of 154 positive samples (85%); 85 positives (55%) were identified using “test 1”. “Test 1” produced
one false positive sample (from the 20 malaria-free control) blood samples; “test 2” produced none. Kappa coefficient
analysis of the results produced a value of 0.267 when microscope-positive blood smears were compared with “test 1”,
but 0.734 when microscope-positive blood smears were compared with the results from “test 2”. Positive predictive
value (PPV) and negative predictive value (NPV) were observed to be 98% and 22% respectively, for “Test 1”, and 99%
and 45%, for “test 2”. No cross reactivity was detected with P. falciparum positive blood samples (n = 15) with either test
assay.
Conclusion: Both tests detected P. vivax infected blood and showed no evidence of cross-reacting with P. falciparum.
Further studies will need to be conducted to establish the full potential of this technique for malaria diagnostics. As
well as representing a promising new cost-effective novel technique for P. vivax diagnosis and research, the method
for developing this assay also highlights the potential for PAb-based strategies for diagnostics in general.
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Background
Malaria is one of the most widespread infectious dis-
eases, carrying with it an enormous cost in human suf-
fering and economic hardship. In 2010 there were an
estimated 216 million cases of the disease [1] and over
half a million deaths attributed to it [2]. Despite great
advancements in many areas of malaria research, light
microscopy-based methods of parasite detection, which
were first developed over a century ago, still remain as
the gold standard and the most commonly used way of
detecting malaria parasites in blood samples [3].
Although this technique is cost-effective and permits
quantitative and qualitative parasite detection, it has
some quite serious limitations. As well as requiring
specialist equipment and staff training, light micros-
copy also needs basic infrastructural support and is
unable to detect very low levels of parasitemia [4,5].
As a result of these limitations, prevalence levels can
be underestimated and diagnostic errors can be made,
which can lead to suboptimal malaria treatment regi-
mens [6,7].
PCR-based malaria detection offers a greater level of
sensitivity than light microscopy [8]; however, it too also
requires specific apparatus, technical experience and
even more complex and expensive infrastructural sup-
port (especially if the technique is required to have a
quantitative dimension) [9]. Thus while PCR has helped
to illuminate the limitations of light microscopy-based
malaria detection, it is still not a major part of routine
malaria parasite detection, especially in remote areas
where malaria can be prevalent.
Immunological assays which use antibodies to detect
parasite molecules offer a fundamentally different ap-
proach to both PCR and light microscopy. Although these
assays can also suffer from sensitivity issues, they have a
far greater potential for adaption to infrastructure-free set-
tings than the other existent approaches. For this reason
Immunological assays have become basis of most com-
mercial diagnostic test kits, with most interest focused on
the use of monoclonal antibodies (MAbs) [10,11]. Almost
all of the malaria rapid diagnostic tests (RDTs) that are
presently available on the commercial market make use of
MAbs to detect the presence of parasite proteins. Al-
though such MAb-based methods offer a potentially
powerful infrastructure-free way of diagnosing the pres-
ence of malaria parasites and are increasingly being used
for this purpose, RDTs are still only used for a small frac-
tion of the hundreds of thousands of malaria diagnoses
made annually [1]. Part of the reason for this is that RDT
test kits are still too expensive for routine usage in devel-
oping counties where most malaria occurs [12] and part
of the reason is that RDTs can be unreliable and often rec-
ommend that diagnosed results are validated with light
microscopy anyway [13-19].
While MAb-based ELISA assays are generally more
sensitive than MAb-based rapid diagnostic tests (RDTs)
and they can offer certain advantages over PCR and light
microscopy for malaria diagnosis, the infrastructure re-
quirements for their use in ELISA assays are similar to
those needed for PCR and light microscopy diagnoses.
In contrast to MAbs, polyclonal-antibodies (PAbs) are
far simpler and cheaper to develop and manufacture
[20] and therefore offer the potential to lower the cost of
both RDTs and laboratory-based ELISA assays for mal-
aria diagnosis and, by doing so, potentially broaden the
appeal of Immunoassays in both laboratory and field set-
tings. PAb–based immunoassays can, however, some-
times be more sensitive to false positives, than MAb-
based assays [21], which is a problem that this paper has
attempted to address.
In this paper we describe the development of a novel
polyclonal based technique for the detection of the
Malaria parasite P. vivax. The technique developed has
avoided cross-reactivity issues by using two polyclonal
antibody sets in concert: one directed to a short portion
of the n-terminal region of the P. vivax lactate dehydro-
genase (PvLDH) and one to a larger over-lapping por-
tion of the same protein.
Methods
Blood sample collection from patients infected with
Plasmodium vivax
Red blood cells (RBC) of 154 patients infected with Plas-
modium vivax were collected between March of 2010
and February of 2011. RBC of 15 patients infected with
P. falciparum were also collected. Plasmodium vivax
and P. falciparum were confirmed with light microscopy.
Secondary laboratory confirmation of P. falciparum
blood infections was obtained by ELISA using an anti-
HRP2 (Histidine rich protein 2) P. falciparum specific
assay, described previously. A control group was formed
with twenty blood samples taken from healthy individ-
uals who were not thought to have been exposed to mal-
aria for more than 6 month. Following collection, all
samples were centrifuged; serum and erythrocytes were
then separated and stored at -20°C until their use in the
ELISA assays, described below.
Recombinant protein production and quality assessment
As a first step in the production of polyclonal antibodies
for detection of native LDH from P. vivax (pvLDHn),
two recombinant proteins were designed (see Figures 1A
and B). The first protein (pvLDH1-43) was designed to
contain the amino acid residues corresponding to posi-
tions 1° to 43° of the pvLDHn protein (i.e. an exten-
sion of the region used successfully by Piper et al.
(1999) [10] in a similar MAb immunoassay and second
protein (pvLDH35-305) was designed to contain the
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amino acid residues from positions 35° to 305° of the
pvLDHn protein (aiming the production of antibodies
capable to interact with a large area of antigen target).
Molecular mass predictions for each of the two de-
signed proteins were made using the program Prot-
param (Expasy).
For Plasmodium vivax genomic DNA extraction,
100 μl of erythrocytes’ sediment was treated with 1%
saponin in Salt phosphate buffer for 20 minutes. After
centrifugation the pellet was resuspended in distilled
water and treated with lysis buffer (40 mM Tris, pH 8;
80 mM EDTA; 2%SDS; 0,1 mg/ml of K-proteinase) for
16 hours. Distilled water was added to make-up each
preparation to a 500 μl volume; five hundred microlitres
of phenol were then added to the preparation and the
resultant 1 ml solution was homogenized and centri-
fuged at 12000 rpm for 5 minutes. After centrifugation,
the aqueous phase was collected and homogenized with
chloroform; 250 μl of the aqueous phase of this prepar-
ation was then added to 45 μl of 3 M of sodium acetate.
Genomic DNA was then precipitated with 100% ethanol.
DNA was then pelleted with centrifugation and then
washed with 70% ethanol and centrifugation.
For production of pvLDH1-43, two oligonucleotide
primers were used to amplify the targeted region for
cloning: the forward primer was 5´ ggatccATGACGCC
GAAACCCAAAATTGT 3´ and reverse primer was 5´



















Figure 1 Recombinant protein production for pvLDH epitope preparations. A) Shows the pvLDH gene sequence targeted for “pvLDH
1-43aa” protein production; PCR primers were used to amplify nucleotide positions 1 to 131 (shown in red and green). For “pvLDH 35-305aa”
protein production, PCR primers were designed to amplify nucleotide positions 82 to 899 (shown in green and blue). B) Shows the corresponding
protein segments “pvLDH 1-43aa” and “pvLDH 35-305aa” that were subsequently cloned and expressed. C) Shows the results from a SDS page gel and
an immunoblot that were used to confirm the successful expression and isolation of a recombinant proteins of the size expected of pvLDH 1-43aa
protein segments. D) Shows the results from a western blot confirming the successful expression and isolation of a recombinant protein of a size
expected for pvLDH 35-305aa recombinant protein segment. NT = Nucleotide; AA = Aminoacids.
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mixture used for PCR amplification was prepared contain-
ing: 1X Taq DNA polymerase buffer, 2.25 nM MgCl2,
0,125 mM dNTP (Invitrogen), 0.6 pMol of each oligo-
nucleotide primer, around 100 pg genomic DNA and 1
unit of Taq polymerase enzyme (Invitrogen) in a final vol-
ume of 50 μL. Sterile distilled water was used to make a
final reaction volume of 25 μl. PCR conditions were as fol-
lows: One initial denaturing step at 94°C for 5 min;
followed by 30 cycles of denaturing at 94°C for 1 minute,
annealing at 69°C for 30 seconds and extending at 72°C for
1 minute; and a final extension step at 72°C for 10 minutes.
The resultant PCR product was purified using a Gel Ex-
tract kit (Qiagen) and then cloned using a commercially
purchased vector (pGEM-T Easy plasmid, Promega) and
competent E. coli cells. A plasmid preparation of pGEM-
pvLDH 1-43aa was then made using a QIAGEN miniprep
kit and digested with the restriction enzymes BamH1 and
EcoR1 (Invitrogen). The digested plasmid insert was then
isolated by gel extraction (using a Qiagen gel extraction
kit) and then directional cloned into an expression vector
using pRSET A (Invitrogen) and E. coli competent cells.
Successful cloning of the targeted gene sequence was then
confirmed by Sanger sequencing the pRSETA-pvLDH 1-
43aa insert in two directions using vector and insert
primers and an Abi 3100 genetic analyzer and recom-
mended reagents and protocols (Applied Biosystems).
After sequence integrity confirmation, purified plasmid
pRSETA-pvLD 1-43aa was used to transform competent
E. coli BL21 (DE3) pLysS cells for expression. Trans-
formed colony isolates were incubated in a 200 ml LB
ampicillin culture at 37°C, with constant agitation until
the cell density provided an OD (optical density) reading
of 0.8. At this point, induction of the gene expression
was initiated with isopropyl β-D-1-thiogalactopyranoside
(IPTG) (at a final working concentration of 1 mM). Fol-
lowing induction, the culture was incubated, as before, for
a further 3 hours. The cell suspension was subsequently
centrifuged at 14 000 rpm, at 4°C, for 15 minutes and the
pelleted cells were resuspended in buffer 2 (20 nM Tris,
pH 7.9; 0.5 M NaCl; 10% glycerol; 1 mM phenylmethane-
sulfonylfluoride), and left, rocking, for 30 minutes. Recom-
binant proteins, contained in the resultant soluble fraction
were decanted from cell debris after centrifugation at
14 000 rpm at 25°C for 15 minutes and were then iso-
lated using Ni-NTA columns (QIAGEN) for purification
of recombinant protein under denaturing conditions, fol-
lowing the manufacture’s recommendations. SDS-PAGE
gels were used to monitor protein expression and purifi-
cation, and an anti-HisG antibody (Invitrogen) immuno-
blot (with Western Breeze kit [Invitrogen]) was used to
ensure the presence of polyhistidine tag in the recombin-
ant protein.
For production of pvLDH35-305, the forward primer
used was 5´ GGATCCATGACGTAGTGAAAA 3´ and
reverse primer used was 5´ GAATTCAACTGCCTCGT
CG 3´. The reaction mixture used for gene amplification
was prepared containing 1X Taq DNA polymerase buf-
fer, with 3 mM MgCl2, 0.15 mM dNTPs, 15 pMol of
each oligonucleotide primer, 100 pg genomic DNA and
1 unit of Taq polymerase enzyme (Invitrogen) in a final
volume of 50 μL. The PCR conditions used for amplifi-
cation were as follows: one initial denaturing step at
94°C for 5 minutes; followed by 30 cycles of a denaturing
step at 94°C for 1 minute followed by an annealing at
62°C for 1 minute and an extension step at 72°C for
1 minute; and then finally a 72°C final extension step
lasting 5 minutes. The resultant PCR product was puri-
fied and cloned into a protein expression vector The ap-
proach used to create and assay protein production from
pGEX3X-pvLDH 35-305aa was very similar to that used
to create from pRSETA-pvLDH 1-43aa. Purification of
GST tagged protein was conducted with a glutathione
sepharose kit following the manufacture’s instructions
(Amershan).
Polyclonal antibodies attainment and purification
Two groups of three mice and one rabbit were immu-
nized separately with pvLDH1-43 protein serum. Mice
and rabbits were stimulated with 50 μg and 500 μg of re-
combinant protein, respectively. Three inoculations were
carried-out in both kinds of animal with intervals of 15
days, using complete freund’s adjuvant in first inoculum
and incomplete freund’s adjuvant in the others. Indirect
ELISA using animal sera were used to monitor humoral
response. The most responsive animals, total serum was
obtained and IgG was purified using Protein A sephar-
ose (Amershan) [22]. Animals were bled and serum
purified in polyclonal antibody preparations with con-
centrations of 1 μg/μL and 6 μg/μL from mice and rab-
bits, respectively. Purified pvLDH35-305 was inoculated
just in mice for this study.
ELISAs for antigen detection
Sandwich ELISAs for LDH P. vivax and P. falciparum
detection were done using rabbit and mouse purified
IgGs. Two systems were tested: a two-site polyclonal
antibody sandwich ELISA using just anti-pvLDH 1-43aa
(coating plates with rabbit antibody and mouse antibody
as primary, (“test 1” Figure 2B), and a two site polyclonal
antibody sandwich ELISA using anti-pvLDH 1-43aa (for
coating) and anti-pvLDH 35-305aa (as primary) (“test 2”,
Figure 2C).
Briefly, ELISA plates were coated with 50 μl of rabbit
polyclonal antibodies anti-pvLDH 1-43aa at a concentra-
tion of 4 μg ⁄mL in sodium bicarbonate buffer (pH 9.6).
The coated plates were incubated at 4°C overnight. After
blocking at 37°C with phosphate buffer containing 5%
skimmed milk (w⁄v) for 2 h, plates were washed with
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phosphate buffer. Test sample (12,5 μL of erythrocyte
concentrate plus 37,5 μL of 0,1% Triton x-100) were then
added in duplicates into the plates and incubated for 1 h
at 37°C. After the washing step with the phosphate buffer,
primary mouse antibody at a concentration of 16 μg/ml
was added. Bound antibodies were detected with HRP
(Horseradish peroxidase) conjugated goat anti-mouse IgG
antibodies (adsorbed to rabbit antibodies, KPL), and rev-
eled using TMB (0.1 mg/ml final concentration), 0,04% f.c.
H2O2, in phosphate-citrate buffer.





Figure 2 pvLDH PAb Sandwich ELISA assays. A) Shows the systems components labeled: 1) Rabbit antibody anti-pvLDH 1-43 aa; 2) Native
LDH (draw based in tetramerical structure described by Chaikuad (2005); 3) Mouse antibody anti- pvLDH 1- 43 aa; 4) Mouse antibody anti-pvLDH
35-305aa; 5) Goat secundary antibody anti-mouse IgG conjugated to HRP. B) Shows a graphic representation of “test 1”. C) Shows a graphic
representation of “test 2”. D) Shows two dot plots illustrating performance of the two PAb assays tests described in main text. Values indicated
on the Y-axis are for optical density measurements. Individual data points are represented with spots. In both test data sets, points from negative
control blood samples are displayed on the right hand side of the plots and those from the microscope slide positive samples are shown on the
left. Solid horizontal lines represent test mean values, dashed lines indicate test cut-off points.
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Alignment and linear B-cell epitopes analyses
Residues 1-43aa of lactate dehydrogenase from P. vivax
(AEP83563.1), P. ovale (AAS77571.1), P. malariae
(AAS77572.1), P. falciparum (ABH03417.1), P. berguie
(AY437808.1), P. knowles (JF958130.1) and P. yoelli (XP_
724101.1) were downloaded from the NCBI protein da-
tabases and then edited manually before being aligned
using Clustal W2. Detection of linear B-cell epitopes
was done using Bepiprep 1.0 server (Larsen & Nielsen,
2006) and a threshold value of 0.2.
Data management and statistical analysis
Data was recorded on registered forms and entered into
a Microsoft Excel spreadsheet (Microsoft Corporation).
Cut-offs were calculated using the mean optical density
readings from negative sample plus twice the standard
deviation of negative samples. Calculation of specificity,
sensitivity, positive predictive and negative predictive
values followed procedures detailed in [23]. Agreement
for results of microscopy and ELISA, and between the two
ELISA methods was calculated with kappa values. A kappa
value between 0.6 and 0.8 was considered a good agree-
ment, higher than 0.8 was considered as excellent [24].
Ethical review
The study was approved by the Brazilian Animal Ethical
Committee (CEEA-UFAM 005/2010) and the Human
Research Ethical Committee of Amazonas Federal Uni-
versity (CAAE 3640.0.000.115-07). All patients signed a
statement of consent.
Results and discussion
Most Malaria immunological assays target one of three
malaria proteins: Histidine rich protein 2 (HRP2), aldol-
ase or lactate dehydrogenase (LDH), all of which are
known to be abundant and detectable in blood serum.
Studies on LDH, however, have shown that blood con-
centrations of the LDH proteins correlate strongly with
parasite blood-levels and thus assays targeting this pro-
tein can have a quantitative dimension. Although the de-
velopment of a quantitative assay what not an initial
goal of this work, and outside the scope of the work pre-
sented here, this feature contributed to its selection as a
target for this work.
DNA sequence analysis confirmed that the two LDH
gene segments that were targeted for this study (pvLDH
1-43aa and pvLDH 35-305aa) were successfully cloned
into plasmid expression vectors. The successful expression
of recombinant proteins from their vectors was confirmed
with Western blot (see Figures 1C and D). Initial sandwich
ELISA assays carried out with the PAbs generated from
the pvLDH 35-305aa showed unacceptably high levels of
cross-reactivity (data not shown) in negative samples, pre-
sumably caused by the presence of native human LDH in
blood samples. The pvLDH 1-43aa PAbs developed here
were specifically designed to combat this issue. Rabbit and
mice PAbs directed to pvLDH 1-43aa, when used in com-
bination as capture and primary antibodies respectively in
“test 1” (see Figure 2B and C), showed unacceptably low
level of parasite detection (only 85 of 154 [55%] micro-
scope positive samples tested positive with this test), al-
though they did not show much evidence of cross
reaction: just one of the malaria-free control group blood
samples (1/20) tested positive for the parasite with this
assay (see Figure 2D). One possible explanation for this
observation is that there is epitope binding competition
between the capture and the primary antibodies used in
this assay. Even though the tetrameric structure of the
antigen [25] might be expected to limit the impact of such
binding competition, such competition affects have been
reported elsewhere [26].
The second sandwich ELISA experiment tested here
was designed to harness the strengths of both assays
and evade the weaknesses. In this assay (see test 2 in
Figure 2D) thus anti-pvLDH pvLDH 1-43aa PAbs were
used as the initial capture antibodies and the anti-pvLDH
35-305aa PAbs were used as primary antibodies. This
test showed higher levels of parasite detection than
were observed for “test 1”: A total of 131 (131/154; 85%)
of the microscopy positive samples tested positive in
this assay and the assay did not generate any false posi-
tives (see Figure 2D). These results show that the tested
pvLDH 35-305aa PAbs are more affective primary anti-
body complements to pvLDH 1-43aa PAbs primary
antibodies than the pvLDH 1-43aa PAbs are. Presumably
this is because the 35-305aa PAbs bind more affectively to
pvLDH 1-43aa-MAb-bound native pvLDH proteins than
1-43aa PAbs do, perhaps because of reduced competition.
Figure 3 Alignment of residue 1-43aa from diferent Plasmodium species. Highlighted amino acids was the detected ones in Bepiprep
(threshold = 0.2). Bold letters and red box represents the diference between P. vivax and P. falciparum at this region.
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The fact that no cross reactivity was observed with this
assay is likely to be a consequence of the removal of human
LDH protein during the ELISA wash steps that preceded
the introduction of the secondary anti-35-305aa PAbs.
Surprisingly, our polyclonal antibodies were not able to
detect parasites in microscope positive (and HRP2 ELISA
confirmed) P. falciparum infected blood samples using ei-
ther the “test 1” or “test 2” methodology (see Figure 3).
Figure 4 shows our pvLDH 1-43aa target protein aligned
to six equivalent segments from other plasmodium species
and shows a region of the protein which has already been
used in the development in a pan-Plasmodium sandwich
ELISA. Although the apparent specificity of our assays
maybe limited to the Amazonian derived P. falciparum
samples we have tested, the low levels of between-species
diversity, which can be seen in Figure 4, occur in protein
regions our bepiprep analysis has predicted are most likely
to be immunogenic and therefore our assay may retain
this specificity for a broader range of P. falciparum strains.
The combination dual-LDH PAb sandwich ELISA
assay described here in test 2 thus represents a poten-
tially powerful low cost tool, which could form the basis
of a variety of immunological assays, for research and
clinical diagnosis and parasite load monitoring. Using
microscopy diagnosed slides as the gold standard, the
positive predictive values (PPV) and negative predictive
values (NPV) calculated for these tests were 98% and
22% (for “test 1”) 99% and 45%, for “test 2”. Kappa coef-
ficient analyses of the results gave a 0.267 value when
blood smears were compared to “test 1”; a 0.734 value
when blood smears were compared to the results from
test “test 2” and a value of 0.367 when both test 1 and 2
results were compared with each other. Although the
potential for this assay to detect submicroscopic levels
of parasitemia has not yet been examined, this assay
compares very favorably when compared to PCR for de-
tecting microscope positive blood samples [4]. Similarly,
when the results from “test 2” are compared with the re-
sults obtained with commercially available MAb-based
immunoassays its performance can be seen to compar-
able [27]. In addition to this, as the blood samples tested
in this assay were all stored frozen prior to use it might
also be that the sensitivity of the test can be improved
with fresh blood samples as Kifude and colleagues
(2008) [28] showed that HRP-2 signal detection reduces
after samples are subjected to freeze and thaw cycles.
Conclusion
In conclusion, the novel LDH targeting PAb-based sand-
wich ELISA “test 2” described here detects P. vivax
microscopy-positive blood samples with an efficiency
similar to what has been observed with MAb-based RDT
kits. Further studies will need to be conducted to establish
if the technique can be adapted to detect submicroscopic
parasitic infections and/or if it can perform better with
fresh blood samples and/or if it can be adapted for a RDT.


































Figure 4 ELISA results of P. falciparum infected blood samples.
Test 1 and 2 did not presented positivite results. Control assay using
anti-HRP2 antibodies detected all positive samples.
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novel technique for P. vivax diagnosis and research, the
method for developing this assay also highlights the po-
tential for PAb-based strategies for diagnostics in general.
It is thus suggested here that the both dual antibody LDH
sandwich ELISA described here and the technique used to
generate it might stimulate further research in this field.
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